However, this therapeutic benefit of TNF-armed MYXV/PBMC therapy, with or without ICI co-therapy, is lost In the later stage advanced disease model (defined as treatment beginning only after a lung disease burden of 5 × 106 luminescence units is achieved). This evidence concerns the gene TNF and lung disorder.